Please login to the form below

Not currently logged in
Email:
Password:

Drug prices

This page shows the latest Drug prices news and features for those working in and with pharma, biotech and healthcare.

US start-up EQRx promises approach that will slash drug prices

US start-up EQRx promises approach that will slash drug prices

Plans to have its first drug on the market in just five years. ... costs. “The time is now for a market-based solution to rising drug costs,” says Borisy.

Latest news

More from news
Approximately 23 fully matching, plus 177 partially matching documents found.

Latest Intelligence

  • The Golden Goose The Golden Goose

    Why it’s so hard for the US to curb runaway drug prices. ... Hard to explain. Politically, reducing drug prices, or at least appearing to do so, has been at the forefront of the federal government’s goals for the past two years.

  • The fight for affordable insulin The fight for affordable insulin

    In April, in response to growing outrage over the problem (and the wider issue of rising drug prices), executives from pharma companies, pharmacy benefit managers (PBMs) and health insurers were hauled ... Recent weeks have seen President Trump shift his

  • The Cystic Fibrosis Buyers’ Club The Cystic Fibrosis Buyers’ Club

    At the same time, Just Treatment is part of a growing movement that is seeking greater data sharing between governments on drug prices, in order to give individual nations more leverage ... Meticulous preparations. The supply of the generic drug comes

  • The rise of CEO activism The rise of CEO activism

    Frazier took to Twitter to make his stand and, within an hour, Trump responded by calling for Mr Frazier to spend his new-found free time “lowering rip-off drug prices”.

  • The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt

    There is no conceivable scenario in which any government would accept the political risk of reducing the threshold: every patient denied access to a drug as a result would be a ... I do not believe the government wants to be trapped in a situation where

More from intelligence
Approximately 2 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The 'winner takes all' pricing game

    Other drivers of price erosion include high prices, high volumes, and tendering by 'winner takes all' where there are alternatives available. ... For the customer, tendering can be an efficient tool for lowering prices, but there are also challenges:.

  • Three strategies for managing loss of exclusivity successfully

    Patent losses could sink Allergan”. “Drug prices to plummet in wave of expiring patents”. ... patent cliff” is an ominous prospect for drug manufacturers – shrouded in the threat of job losses and falling share prices.

  • Oncology drugs under AMNOG

    Part 1: Segmentation and comparator choice - lessons for cancer drug market access in Germany. ... How to prepare. Germany is one of the largest pharmaceutical markets in Europe and drug prices there are used as reference prices in other markets.

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics